Skip to main content

Advertisement

Table 2 Baseline characteristics of patients included

From: Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

Baseline characteristics AL (1996–2014) ASAQ (2002–2014) ASMQ (2002–2013) DP (2002–2013) Total (1996–2014)
N 16,373 4850 1220 9064 31,507
Gender
 Femalea 7394 (45.2%) 2253 (46.5%) 591 (48.4%) 3464 (38.2%) 13,702 (43.5%)
Age (years)a
 Mean age ± SD (years) 8.3 ± 10.66 7.0 ± 9.21 11.9 ± 13.37 13.5 ± 14.09 9.8 ± 11.94
 < 1 year 924 (5.6%) 312 (6.4%) 65 (5.3%) 386 (4.3%) 1687 (5.4%)
 1 to < 5 years 8629 (52.7%) 2895 (59.7%) 522 (42.8%) 3736 (41.2%) 15,782 (50.1%)
 5 to < 12 years 3306 (20.2%) 773 (15.9%) 201 (16.5%) 1264 (13.9%) 5544 (17.6%)
 ≥ 12 years 3491 (21.3%) 862 (17.8%) 426 (34.9%) 3665 (40.4%) 8444 (26.8%)
 Missing 23 (0.1%) 8 (0.2%) 6 (0.5%) 13 (0.1%) 50 (0.2%)
Continenta
 Africa 14,087 (86.0%) 4550 (93.8%) 810 (66.4%) 4862 (53.6%) 24,309 (77.2%)
 Asia 2127 (13.0%) 300 (6.2%) 410 (33.7%) 3950 (43.6%) 6787 (21.5%)
 South America 159 (1.0%) 0 (0.0%) 0 (0.0%) 252 (2.8%) 411 (1.3%)
Enrolment clinical parameters
 Mean body weight ± SD (kg) 20.9 ± 16.29 20.0 ± 16.02 23.7 ± 17.2 22.4 ± 17.55 21.2 ± 16.63
 Mean haemoglobin ± SD (g/dL) 10.2 ± 2.21 9.6 ± 1.98 10.4 ± 2.26 10.2 ± 2.31 10.1 ± 2.22
 Median parasitaemia [IQR] (/µL) 19,674 [5590–50,550] 21,730 [7353–53,439] 23,386 [5953–64,103] 14,320 [4178–43,337] 18,576 [5284–49,520]
 Elevated temperature (> 37.5°) 64.3% [9705/15,101] 67.9% [3221/4747] 74.0% [743/1004] 60.2% [4200/6972] 64.2% [17,869/27,824]
  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, ASMQ artesunate–mefloquine, DP dihydroartemisinin–piperaquine, IQR interquartile range, SD standard deviation, N number of patients
  2. aColumn percentages presented in parenthesis